magnesium gluconate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4515 3632-91-5

Description:

MoleculeDescription

Synonyms:

  • magnesium D-gluconate
  • magnesium gluconate
  • glucomag
  • Molecular weight: 414.60
  • Formula: C12H22MgO14
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 141.28
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
5 g O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Body tinea 114.51 16.43 25 3980 2123 90622319
Inhibitory drug interaction 104.88 16.43 25 3980 3138 90621304
Infection susceptibility increased 99.51 16.43 25 3980 3901 90620541
Glucose tolerance impaired 90.55 16.43 27 3978 7958 90616484
Discoloured vomit 81.29 16.43 17 3988 1175 90623267
Purpura 66.85 16.43 25 3980 14753 90609689
Bone density decreased 66.47 16.43 26 3979 17319 90607123
Hyperlipidaemia 62.74 16.43 27 3978 22889 90601553
Poor quality sleep 57.61 16.43 26 3979 24667 90599775
Impaired work ability 53.66 16.43 23 3982 19303 90605139
Internal haemorrhage 53.43 16.43 17 3988 6203 90618239
Oral herpes 52.94 16.43 27 3978 33497 90590945
Skin disorder 50.63 16.43 27 3978 36679 90587763
Impaired quality of life 49.68 16.43 23 3982 23121 90601321
Cataract 42.82 16.43 31 3974 72061 90552381
Hallucination, auditory 41.04 16.43 18 3987 15957 90608485
Cellulitis 38.39 16.43 32 3973 91305 90533137
Respiratory arrest 26.09 16.43 17 3988 33294 90591148
Herpes zoster 25.75 16.43 26 3979 94618 90529824
Underdose 20.78 16.43 18 3987 53999 90570443
Contusion 19.95 16.43 38 3967 251178 90373264
Insomnia 17.88 16.43 43 3962 333431 90291011
Myofascial pain syndrome 17.00 16.43 6 3999 3001 90621441
Periarthritis 16.94 16.43 6 3999 3031 90621411

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
SARS-CoV-2 sepsis 80.74 31.86 12 877 243 42620203
Fractional exhaled nitric oxide increased 35.86 31.86 8 881 1601 42618845
Exostosis 34.62 31.86 10 879 5621 42614825

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Body tinea 111.40 18.28 24 4455 2091 110582729
Infection susceptibility increased 103.82 18.28 26 4453 4372 110580448
Inhibitory drug interaction 91.12 18.28 24 4455 4923 110579897
Glucose tolerance impaired 78.95 18.28 25 4454 9812 110575008
Discoloured vomit 73.86 18.28 17 4462 2000 110582820
SARS-CoV-2 sepsis 72.26 18.28 12 4467 253 110584567
Bone density decreased 66.97 18.28 25 4454 16017 110568803
Purpura 53.62 18.28 24 4455 24364 110560456
Hyperlipidaemia 50.54 18.28 26 4453 35822 110548998
Poor quality sleep 50.38 18.28 24 4455 28053 110556767
Oral herpes 50.38 18.28 26 4453 36054 110548766
Internal haemorrhage 46.85 18.28 17 4462 10054 110574766
Skin disorder 43.45 18.28 25 4454 42888 110541932
Impaired quality of life 42.97 18.28 22 4457 29995 110554825
Impaired work ability 39.67 18.28 20 4459 26399 110558421
Fractional exhaled nitric oxide increased 36.35 18.28 8 4471 768 110584052
Hallucination, auditory 33.93 18.28 18 4461 26379 110558441
Cellulitis 33.79 18.28 33 4446 125983 110458837
Cataract 31.59 18.28 26 4453 79459 110505361
Myoglobin blood increased 22.92 18.28 8 4471 4224 110580596
Underdose 21.59 18.28 19 4460 63535 110521285
Plantar fasciitis 21.47 18.28 8 4471 5093 110579727
Herpes zoster 21.21 18.28 24 4455 108355 110476465
Fatigue 20.37 18.28 100 4379 1215858 109368962
Contusion 20.35 18.28 35 4444 233326 110351494
Exostosis 20.31 18.28 16 4463 45940 110538880
Respiratory arrest 18.94 18.28 17 4462 58282 110526538
Myofascial pain syndrome 18.43 18.28 6 4473 2567 110582253
Brain natriuretic peptide increased 18.35 18.28 9 4470 11200 110573620

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A12CC03 ALIMENTARY TRACT AND METABOLISM
MINERAL SUPPLEMENTS
OTHER MINERAL SUPPLEMENTS
Magnesium

Related Drugs by ATC class:

A12CC Magnesium 9 drugs
magnesium aspartatemagnesium chloridemagnesium citratemagnesium lactatemagnesium levulinatemagnesium orotatemagnesium oxidemagnesium pidolatemagnesium sulfate

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Constipation indication 14760008 DOID:2089
Indigestion indication 162031009
Hypomagnesemia indication 190855004
Incomplete passage of stool indication 249515001
Diarrhea contraindication 62315008
Kidney disease contraindication 90708001 DOID:557




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D04835 KEGG_DRUG
4020251 VUID
N0000148148 NUI
59625-89-7 SECONDARY_CAS_RN
4020249 VANDF
4020251 VANDF
CHEBI:756214 CHEBI
CHEMBL3989640 ChEMBL_ID
C030691 MESH_SUPPLEMENTAL_RECORD_UI
DB13749 DRUGBANK_ID
T42NAD2KHC UNII
52358 RXNORM
5006 MMSL
5012 MMSL
5576 MMSL
d03798 MMSL
000787 NDDF
C0126777 UMLSCUI
71587201 PUBCHEM_CID
T42NAD2KHC INXIGHT DRUGS

Pharmaceutical products:

None